369 SOUTH SAN ANTONIO RD., LOS ALTOS, CA
Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting
Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Changes in Board, Management or Compensation
Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203
Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway
Financial Results, Shareholder votes
Annual Report to Security Holders
Reports Full-Year 2024 Financial Results and Recent Business Highlights
Q2
Q1
FY 2024
Q3
FY 2023
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(4)
Certificate
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Definitive Revised Proxy Statement